You just read:

Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals

News provided by

Provention Bio, Inc.

Aug 05, 2019, 07:00 ET